{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T09:43:09Z","timestamp":1792489389631,"version":"4.5.0"},"reference-count":21,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["NHMRC APP2033152"],"award-info":[{"award-number":["NHMRC APP2033152"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015521","name":"Stanford Maternal and Child Health Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015521","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>\n                    Inotuzumab ozogamicin (InO) is approved by the U.S. Food and Drug Administration (FDA) for relapsed\/refractory (R\/R) B\u2010cell acute lymphoblastic leukaemia (B\u2010ALL), with a standard schedule of 1.8\u2009mg\/m\n                    <jats:sup>2<\/jats:sup>\n                    fractionated into three doses for cycle 1. Alternative dosing with fewer doses or lower cumulative doses may be considered to minimize toxicity or expedite transition to consolidative therapy, though data on the efficacy and toxicity of this approach are limited. We conducted a multi\u2010institutional retrospective analysis of 72 paediatric, adolescent and young adult (AYA) patients receiving at least one InO dose; 41 with standard dosing and 31 with alternative dosing. Between the two approaches, standard dosing was associated with improved composite complete response (CRc); however, there was no difference in ability to proceed to consolidative cellular therapy, nor differences in 2\u2010year event\u2010free or overall survival. Ten per cent of patients experienced sinusoidal obstruction syndrome (SOS), all following haematopoietic stem cell transplant. Most cases occurred in patients receiving standard InO dosing; however, given the overall few cases, it is unclear if this is due to a difference in dosing regimen. In conclusion, this large real\u2010world study of InO use in the paediatric\/AYA R\/R B\u2010ALL population suggests using alternate InO dosing strategies can successfully bridge patients to consolidative therapy with no difference in outcomes compared with standard dosing.\n                  <\/jats:p>","DOI":"10.1111\/bjh.70892","type":"journal-article","created":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T09:25:45Z","timestamp":1792488345000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A real\u2010world multi\u2010institution experience of standard versus alternative dosing regimens of inotuzumab ozogamicin for relapsed\/refractory paediatric B\u2010cell acute lymphoblastic leukaemia"],"prefix":"10.1111","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-1259-3988","authenticated-orcid":false,"given":"Morgan","family":"Drucker","sequence":"first","affiliation":[{"name":"Division of Oncology, Cancer &amp; Blood Diseases Institute Cincinnati Children's Hospital Medical Center  Cincinnati Ohio USA"},{"name":"Department of Pediatrics University of Cincinnati College of Medicine  Cincinnati Ohio USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Lane","sequence":"additional","affiliation":[{"name":"Division of Oncology, Cancer &amp; Blood Diseases Institute Cincinnati Children's Hospital Medical Center  Cincinnati Ohio USA"},{"name":"Department of Pediatrics University of Cincinnati College of Medicine  Cincinnati Ohio USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9775-2839","authenticated-orcid":false,"given":"Catherine","family":"Aftandilian","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Hematology, Oncology, Stem Cell Transplant and Regenerative Medicine Stanford University  Stanford California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7182-2592","authenticated-orcid":false,"given":"Kara L.","family":"Davis","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Hematology, Oncology, Stem Cell Transplant and Regenerative Medicine Stanford University  Stanford California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8025-6767","authenticated-orcid":false,"given":"Susan R.","family":"Rheingold","sequence":"additional","affiliation":[{"name":"Division of Oncology and Cellular Therapy Children's Hospital of Philadelphia  Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisha","family":"Ball","sequence":"additional","affiliation":[{"name":"Division of Oncology and Cellular Therapy Children's Hospital of Philadelphia  Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8240-7490","authenticated-orcid":false,"given":"Kelly E.","family":"Faulk","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Center for Cancer and Blood Disorders, Children's Hospital Colorado, University of Colorado, Anschutz Medical Campus  Aurora Colorado USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9054-4321","authenticated-orcid":false,"given":"Maureen M.","family":"O'Brien","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Center for Cancer and Blood Disorders, Children's Hospital Colorado, University of Colorado, Anschutz Medical Campus  Aurora Colorado USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5671-8925","authenticated-orcid":false,"given":"Jamie","family":"Stokke","sequence":"additional","affiliation":[{"name":"Division of Hematology\u2010Oncology, Children's Hospital Los Angeles, Keck School of Medicine University of Southern California  Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7559-7927","authenticated-orcid":false,"given":"Deepa","family":"Bhojwani","sequence":"additional","affiliation":[{"name":"Division of Hematology\u2010Oncology, Children's Hospital Los Angeles, Keck School of Medicine University of Southern California  Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1836-4075","authenticated-orcid":false,"given":"Rishi S.","family":"Kotecha","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology, Oncology, Blood and Marrow Transplantation Perth Children's Hospital  Perth WA Australia"},{"name":"Leukaemia Translational Research Laboratory, WA Kids Cancer Centre, the Kids Research Institute Australia University of Western Australia  Perth WA Australia"},{"name":"Curtin Medical School Curtin University  Perth WA Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1934-2954","authenticated-orcid":false,"given":"Jeremy D.","family":"Rubinstein","sequence":"additional","affiliation":[{"name":"Division of Oncology, Cancer &amp; Blood Diseases Institute Cincinnati Children's Hospital Medical Center  Cincinnati Ohio USA"},{"name":"Department of Pediatrics University of Cincinnati College of Medicine  Cincinnati Ohio USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,20]]},"reference":[{"issue":"9","key":"e_1_2_12_2_1","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2411680","article-title":"Blinatumomab in standard\u2010risk B\u2010cell acute lymphoblastic leukemia in children","volume":"392","author":"Gupta S","year":"2025","journal-title":"N Engl J Med"},{"issue":"6","key":"e_1_2_12_3_1","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.30585","article-title":"Children's oncology group blueprint for research: acute lymphoblastic leukemia","volume":"70","author":"Raetz EA","year":"2023","journal-title":"Pediatr Blood Cancer"},{"key":"e_1_2_12_4_1","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1038\/s41375-024-02395-4","article-title":"Determinants of survival after first relapse of acute lymphoblastic leukemia: a Children's oncology group study","volume":"38","author":"Rheingold S","year":"2024","journal-title":"Leukemia"},{"issue":"31","key":"e_1_2_12_5_1","doi-asserted-by":"crossref","first-page":"7942","DOI":"10.1200\/JCO.2005.01.1031","article-title":"Long\u2010term outcomes in children with relapsed ALL by risk\u2010stratified salvage therapy: results of trial acute lymphoblastic leukemia\u2010relapse study of the Berlin\u2010Frankfurt\u2010Munster group 87","volume":"23","author":"Einsiedel HG","year":"2005","journal-title":"J Clin Oncol"},{"key":"e_1_2_12_6_1","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1038\/leu.2008.251","article-title":"Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's oncology group study","volume":"22","author":"Nguyen K","year":"2008","journal-title":"Leukemia"},{"issue":"9","key":"e_1_2_12_7_1","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1001\/jama.2021.0669","article-title":"Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease\u2010free survival in children, adolescents, and young adults with first relapse of B\u2010cell acute lymphoblastic leukemia: a randomized clinical trial","volume":"325","author":"Brown PA","year":"2021","journal-title":"JAMA"},{"issue":"5","key":"e_1_2_12_8_1","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B\u2010cell lymphoblastic leukemia","volume":"378","author":"Maude SL","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"e_1_2_12_9_1","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.30271","article-title":"Durable remission achieved with reinfusion of CD19\u2010directed CAR\u2010T despite failure to induce or maintain B\u2010cell aplasia and single\u2010center experience with reinfusion of tisagenlecleucel","volume":"70","author":"Galleta TJ","year":"2023","journal-title":"Pediatr Blood Cancer"},{"issue":"14","key":"e_1_2_12_10_1","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1002\/cncr.32116","article-title":"Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: final report and long\u2010term survival follow\u2010up from the randomized, phase 3 INO\u2010VATE study","volume":"125","author":"Kantarjian HM","year":"2019","journal-title":"Cancer"},{"issue":"8","key":"e_1_2_12_11_1","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1080\/10428194.2020.1751839","article-title":"Impact of salvage treatment phase on inotuzumab ozogamicin treatment for relapsed\/refractory acute lymphoblastic leukemia: an update from the INO\u2010VATE final study database","volume":"61","author":"Jabbour E","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"e_1_2_12_12_1","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1182\/blood.2020007848","article-title":"A phase 1 study of inotuzumab ozogamicin in pediatric relapsed\/refractory acute lymphoblastic leukemia (ITCC\u2010059 study)","volume":"137","author":"Brivio E","year":"2021","journal-title":"Blood"},{"key":"e_1_2_12_13_1","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1200\/JCO.21.01693","article-title":"Phase II trial of inotuzumab ozogamicin in children and adolescents with relapsed or refractory B\u2010cell acute lymphoblastic leukemia: Children's oncology group protocol AALL1621","volume":"40","author":"O'Brien MM","year":"2022","journal-title":"J Clin Oncol"},{"key":"e_1_2_12_14_1","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35820","article-title":"INO\u2010CD22: a multicenter, real\u2010world study of inotuzumab ozogamicin safety and effectiveness in adult patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"131","author":"Papayannidis C","year":"2025","journal-title":"Cancer"},{"issue":"5","key":"e_1_2_12_15_1","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.3324\/haematol.2023.284310","article-title":"Impact of inotuzumab ozogamicin on outcome in relapsed or refractory acute B\u2010cell lymphoblastic leukemia patients prior to allogeneic hematopoietic stem cell transplantation and risk of sinusoidal obstruction syndrome\/venous occlusive disease","volume":"109","author":"Kayser S","year":"2024","journal-title":"Haematologica"},{"issue":"8","key":"e_1_2_12_16_1","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.clml.2020.03.004","article-title":"Real\u2010world outcomes of adult B\u2010cell acute lymphocytic leukemia patients treated with inotuzumab ozogamicin","volume":"20","author":"Badar T","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"19","key":"e_1_2_12_17_1","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.2217\/fon-2022-1314","article-title":"Real\u2010world treatment patterns of novel drugs in relapsed or refractory acute lymphoblastic leukemia patients in Japan","volume":"19","author":"Moribe T","year":"2023","journal-title":"Future Oncol"},{"issue":"6","key":"e_1_2_12_18_1","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1111\/bjh.17333","article-title":"Inotuzumab ozogamicin in infants and young children with relapsed or refractory acute lymphoblastic leukaemia: a case series","volume":"193","author":"Brivio E","year":"2021","journal-title":"Br J Haematol"},{"issue":"20","key":"e_1_2_12_19_1","doi-asserted-by":"crossref","first-page":"4044","DOI":"10.1002\/cncr.31720","article-title":"Chemoimmunotherapy with inotuzumab ozogamicin combined with mini\u2010hyper\u2010CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome\u2010negative acute lymphoblastic leukemia in first salvage","volume":"124","author":"Jabbour E","year":"2018","journal-title":"Cancer"},{"key":"e_1_2_12_20_1","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.e19017","article-title":"A phase II study of hyper\u2010CVAD with blinatumomab (blina) and inotuzumab ozogamicin (INO) for newly diagnosed Philadelphia chromosome (Ph)\u2010negative B\u2010cell acute lymphoblastic leukemia (ALL)","volume":"41","author":"Short NJ","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"e_1_2_12_21_1","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1182\/blood-2019-125340","article-title":"SWOG 1312 final results: a phase 1 trial of inotuzumab in combination with CVP (cyclophosphamide, vincristine, prednisone) for relapsed\/refractory CD22+ acute leukemia","volume":"134","author":"Advani AS","year":"2019","journal-title":"Blood"},{"key":"e_1_2_12_22_1","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1038\/s41375-022-01576-3","article-title":"Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial","volume":"36","author":"Pennesi E","year":"2022","journal-title":"Leukemia"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.70892","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.70892","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.70892","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T09:25:48Z","timestamp":1792488348000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.70892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,20]]},"references-count":21,"alternative-id":["10.1111\/bjh.70892"],"URL":"https:\/\/doi.org\/10.1111\/bjh.70892","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,20]]},"assertion":[{"value":"2026-06-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"bjh.70892"}}